News and Announcements
YPB Takes First Step into Pharmaceutical Industry
- Published July 01, 2016 4:04PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st July 2016, ASX Announcement
Highlights:
- Three-year supply contract with Universal Pharmaceuticals Ltd for the provision of YPB’s anti-counterfeit and consumer engagement technologies
- Universal Pharmaceuticals – Australian company exporting pharmaceuticals products to growing Chinese and South East Asian markets
- Reflects greater awareness of potential counterfeit issues in the Australian pharmaceutical industry and importance of brand protection
YPB Group Limited (ASX:YPB) has entered into a supply contract with Universal Pharmaceuticals, a NSW-based pharmaceutical company exporting quality pharmaceuticals to the rapidly-growing Asian market.
Under the contract YPB will provide its invisible covert tracer technology to Universal Pharmaceuticals.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
